441 related articles for article (PubMed ID: 27435882)
1. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
[TBL] [Abstract][Full Text] [Related]
2. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
3. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
4. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
[TBL] [Abstract][Full Text] [Related]
5. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G
Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
[TBL] [Abstract][Full Text] [Related]
6. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
[TBL] [Abstract][Full Text] [Related]
8. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.
Konstan MW; Flume PA; Galeva I; Wan R; Debonnett LM; Maykut RJ; Angyalosi G
Pediatr Pulmonol; 2016 Apr; 51(4):372-8. PubMed ID: 26709158
[TBL] [Abstract][Full Text] [Related]
9. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.
Trapnell BC; McColley SA; Kissner DG; Rolfe MW; Rosen JM; McKevitt M; Moorehead L; Montgomery AB; Geller DE;
Am J Respir Crit Care Med; 2012 Jan; 185(2):171-8. PubMed ID: 22095545
[TBL] [Abstract][Full Text] [Related]
10. Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough.
Meerburg JJ; Albasri M; van der Wiel EC; Andrinopoulou ER; van der Eerden MM; Majoor CJ; Arets HGM; Heijerman HGM; Tiddens HAWM
Pediatr Pulmonol; 2019 Nov; 54(11):1794-1800. PubMed ID: 31393073
[TBL] [Abstract][Full Text] [Related]
11. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.
Galeva I; Konstan MW; Higgins M; Angyalosi G; Brockhaus F; Piggott S; Thomas K; Chuchalin AG
Curr Med Res Opin; 2013 Aug; 29(8):947-56. PubMed ID: 23672633
[TBL] [Abstract][Full Text] [Related]
12. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
13. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.
Hamed K; Debonnett L
Ther Adv Respir Dis; 2017 May; 11(5):193-209. PubMed ID: 28470103
[TBL] [Abstract][Full Text] [Related]
14. Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.
Panguluri S; Gunda P; Debonnett L; Hamed K
Clin Drug Investig; 2017 Aug; 37(8):795-805. PubMed ID: 28643178
[TBL] [Abstract][Full Text] [Related]
15. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
16. An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
Sutharsan S; Naehrig S; Mellies U; Sieder C; Ziegler J
BMC Pulm Med; 2020 Jun; 20(1):167. PubMed ID: 32532226
[TBL] [Abstract][Full Text] [Related]
17. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Bilton D; Pressler T; Fajac I; Clancy JP; Sands D; Minic P; Cipolli M; Galeva I; Solé A; Quittner AL; Liu K; McGinnis JP; Eagle G; Gupta R; Konstan MW;
J Cyst Fibros; 2020 Mar; 19(2):284-291. PubMed ID: 31451351
[TBL] [Abstract][Full Text] [Related]
18. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
Hodson ME; Gallagher CG; Govan JR
Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344
[TBL] [Abstract][Full Text] [Related]
19. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA;
Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
[TBL] [Abstract][Full Text] [Related]
20. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.
Stuart Elborn J; Geller DE; Conrad D; Aaron SD; Smyth AR; Fischer R; Kerem E; Bell SC; Loutit JS; Dudley MN; Morgan EE; VanDevanter DR; Flume PA
J Cyst Fibros; 2015 Jul; 14(4):507-14. PubMed ID: 25592656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
